Phase 1 and Phase 2a, First-in-human (FIH) Study, of DRP-104, a Broad Glutamine Antagonist, in Adult Patients with Advanced Solid Tumors.
JOURNAL OF CLINICAL ONCOLOGY(2021)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined